Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from PDS Biotechnology ( (PDSB) ).
On December 9, 2025, PDS Biotechnology Corporation announced that the Japan Patent Office issued a new patent for PDS0101, expanding its intellectual property estate. This development strengthens the company’s global IP portfolio, providing patent and market protections for PDS0101 into the 2040s, and supports the company’s growth as it advances its pipeline worldwide.
The most recent analyst rating on (PDSB) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on PDS Biotechnology stock, see the PDSB Stock Forecast page.
Spark’s Take on PDSB Stock
According to Spark, TipRanks’ AI Analyst, PDSB is a Neutral.
PDSB’s overall score reflects the typical high-risk, high-reward nature of early-stage biotech firms. The company’s strong clinical progress and cash position are significant positives, but financial sustainability and valuation concerns due to ongoing losses and reliance on external funding temper the outlook. Technical indicators suggest some positive momentum, albeit with caution.
To see Spark’s full report on PDSB stock, click here.
More about PDS Biotechnology
PDS Biotechnology is a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers. The company is advancing its lead program in advanced HPV16-positive head and neck squamous cell cancers, with its lead investigational targeted immunotherapy PDS0101 being developed in combination with a standard-of-care immune checkpoint inhibitor.
Average Trading Volume: 759,533
Technical Sentiment Signal: Sell
Current Market Cap: $47.61M
For an in-depth examination of PDSB stock, go to TipRanks’ Overview page.